Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Aug 22 (Reuters) -Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
The U.S. initial public offering market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility.
Zenas BioPharma, an immunology and inflammation focused biopharma company, said it has raised $358.3 million from investors since its inception.
The company's investors include Tellus BioVentures, Fairmount, Norwest Venture Partners, Enavate Sciences and Bristol-Myers Squibb BMY.N.
The firm's losses widened to $65.8 million for the six months ended June 30, compared with $48.1 million, a year earlier. It did not reveal the number of shares it planned to sell and the proposed price range.
The company expects its shares to trade on the Nasdaq Global Market under the ticker symbol 'ZBIO'. Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities are the underwriters.
Reporting by Manya Saini in Bengaluru; Editing by Arun Koyyur
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
